{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:45:30Z","timestamp":1792133130945,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clnesp.2026.105169","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:06:23Z","timestamp":1791821183000},"page":"105169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterizing the adverse event profile of semaglutide: A comprehensive U.S. food and drug administration adverse event reporting system-based pharmacovigilance study"],"prefix":"10.1016","volume":"76","author":[{"given":"Sunaina A.","family":"Thawkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi R.","family":"Singare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-1920","authenticated-orcid":false,"given":"Nikhil S.","family":"Sakle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clnesp.2026.105169_bib1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnesp.2026.105169_bib2","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnesp.2026.105169_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105169_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000475","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System","volume":"6","author":"Fadini","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clnesp.2026.105169_bib5","article-title":"GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105169_bib6","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis","volume":"66","author":"Chen","year":"2023","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clnesp.2026.105169_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnesp.2026.105169_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic adverse events","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clnesp.2026.105169_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1364110","article-title":"Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.clnesp.2026.105169_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40264-016-0491-0","article-title":"Evaluation of social media monitoring for drug safety signals","volume":"40","author":"Pierce","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.clnesp.2026.105169_bib11","article-title":"Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105169_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pop.2015.08.011","article-title":"Past, Present, and Future of Pharmacologic Therapy in Obesity","volume":"43","author":"Rodr\u00edguez","year":"2016","journal-title":"Prim Care"},{"key":"10.1016\/j.clnesp.2026.105169_bib13","article-title":"Ozempic controversy and weight loss trends","author":"Jamil","year":"2023","journal-title":"Independent"},{"key":"10.1016\/j.clnesp.2026.105169_bib14","doi-asserted-by":"crossref","DOI":"10.2196\/24336","article-title":"Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter","volume":"23","author":"Alvarez-Mon","year":"2021","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.clnesp.2026.105169_bib15","series-title":"Ozempic misuse alert","year":"2023"},{"key":"10.1016\/j.clnesp.2026.105169_bib16","series-title":"Ozempic promotion concerns","year":"2023"},{"key":"10.1016\/j.clnesp.2026.105169_bib17","series-title":"What You Need to Know About Ozempic: the Diabetes Drug Fueling Hollywood\u2019s Harmful Weight-Loss Obsession","author":"Valdesolo","year":"2023"},{"key":"10.1016\/j.clnesp.2026.105169_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/hup.2466","article-title":"Profiling online recreational\/prescription drugs' customers and overview of drug vending virtual marketplaces","volume":"30","author":"Orsolini","year":"2015","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clnesp.2026.105169_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275272","article-title":"Facebook as a source of medicines","volume":"17","author":"Zaprutko","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clnesp.2026.105169_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clnesp.2026.105169_bib21","article-title":"Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data","volume":"14","author":"Farnoush","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2026.105169_bib22","article-title":"Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clnesp.2026.105169_bib23","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1002\/cam4.4343","article-title":"Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: an observational, retrospective, pharmacovigilance study leveraging US FARES database","volume":"10","author":"Hu","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clnesp.2026.105169_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1561942","article-title":"PD-1\/PD-L1 inhibitor-induced hyponatremia: a real-world pharmacovigilance analysis using FAERS database","volume":"16","author":"Tao","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clnesp.2026.105169_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110638","article-title":"Drug-Related epileptic seizures and Age-Specific Differences: A Real-World study based on the FAERS database","volume":"171","author":"Wang","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.clnesp.2026.105169_bib26","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3390\/diagnostics14242829","article-title":"Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.clnesp.2026.105169_bib27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s13300-024-01594-7","article-title":"Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023","volume":"15","author":"Xiong","year":"2024","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.clnesp.2026.105169_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in Obese individuals without diabetes: a systematic review and Meta analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Saudi Med J"},{"issue":"21","key":"10.1016\/j.clnesp.2026.105169_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038236","article-title":"Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: a meta-analysis","volume":"103","author":"Huang","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.clnesp.2026.105169_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.clnesp.2026.105169_bib31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/dom.14944","article-title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","volume":"25","author":"Jensterle","year":"2023","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.clnesp.2026.105169_bib32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.14309\/ajg.0000000000002820","article-title":"Quantified metrics of gastric emptying delay by glucagon-like Peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management","volume":"119","author":"Hiramoto","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.clnesp.2026.105169_bib33","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1111\/dom.15802","article-title":"Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial","volume":"26","author":"Gabe","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.clnesp.2026.105169_bib34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or Obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnesp.2026.105169_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clnesp.2026.105169_bib36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s13300-026-01872-6","article-title":"Integrated evidence from VigiBase and clinical trials: a comprehensive pharmacovigilance analysis of seven glucagon-like peptide 1 receptor agonists (GLP-1 RAs)","volume":"17","author":"Li","year":"2026","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clnesp.2026.105169_bib37","author":"Advisor"},{"key":"10.1016\/j.clnesp.2026.105169_bib38","series-title":"Semaglutide and eye disorder","year":"2024"},{"key":"10.1016\/j.clnesp.2026.105169_bib39","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.bja.2024.10.013","article-title":"Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system","volume":"134","author":"Huang","year":"2024","journal-title":"Br J Anaesth"},{"issue":"10","key":"10.1016\/j.clnesp.2026.105169_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.40890","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clnesp.2026.105169_bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s44263-024-00095-w","article-title":"Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using google trends extended for health application programming interface","volume":"2","author":"Raubenheimer","year":"2024","journal-title":"BMC Glob Public Health"},{"key":"10.1016\/j.clnesp.2026.105169_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41366-024-01524-4","article-title":"Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study","volume":"49","author":"Craig","year":"2025","journal-title":"Int J Obes"},{"key":"10.1016\/j.clnesp.2026.105169_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.clnesp.2026.105169_bib44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clnesp.2026.105169_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40360-024-00789-9","article-title":"Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database","volume":"25","author":"Yang","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"issue":"Suppl 1","key":"10.1016\/j.clnesp.2026.105169_bib46","article-title":"Pharmacovigilance Signals of Semaglutide and Other Glp-1 Receptor Agonists: An Analysis of The Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) Dataset","volume":"28","author":"Chiappini","year":"2025","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726022667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726022667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:59:25Z","timestamp":1792130365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726022667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":46,"alternative-id":["S2405457726022667"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.105169","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing the adverse event profile of semaglutide: A comprehensive U.S. food and drug administration adverse event reporting system-based pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.105169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105169"}}